Atlas Trials

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Clinical trial NCT05920798 · RECRUITING

Trial details

NCT number
NCT05920798
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Fallopian Tube CarcinosarcomaPrimary Peritoneal CarcinosarcomaRecurrent Fallopian Tube CarcinomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian CarcinosarcomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Primary Peritoneal Carcinoma
Start date
2023-09-28
Primary completion
2028-06-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.